deexa-g eye/ear drop 0,01+0.03
lincoln pharmaceuticals limited, india - dexamethasone , gentamycin - eye/ear drop - 0,01+0.03
provist-opto 5 mg/ml eye drops, solution in single-dose container
uni-pharma kleon tsetis pharmaceutical laboratories s.a. 14th km national road athens - lamia 1, gr-145 64 kifissia, greece - eye drops, solution - prednisolone 5 mg/ml - ophthalmologicals
ecitapram-20 film coated tablet
lincoln pharmaceuticals limited, india - escitalopram tablets usp - film coated tablet - 20
pharmapress 10 mg tablet
pharmacare limited û woodmead - tablet - see ingredients - each tablet contains enalapril maleate 10,0 mg
pharmapress 20 mg tablet
pharmacare limited û woodmead - tablet - see ingredients - each tablet contains enalapril maleate 20,0 mg
pharmapress co tablet
pharmacare limited û woodmead - tablet - see ingredients - each tablet contains enalapril maleate 20,0 mg hydrochlorothiazide 12,5 mg
pharmapress 5 mg tablet
pharmacare limited û woodmead - tablet - see ingredients - each tablet contains enalapril maleate 5,0 mg
essentially pets allwormer for cats and kittens
essentially pets (vic) pty ltd - niclosamide; pyrantel embonate - oral paste - niclosamide anthelmintic active 300.0 mg/ml; pyrantel embonate anthelmintic active 115.2 mg/ml - parasiticides - cat | kitten | cat - queen | cat - tom | kitten | young cat - hookworm - ancylostoma spp. | hookworm - uncinaria spp. | roundworm | roundworm - toxascaris spp. | tapeworm - dipylidium spp. | tapeworm - taenia spp. | toxocara mystax | toxocara spp.
hydralazine hydrochloride tablet
cadila pharmaceuticals limited - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8) - hydralazine hydrochloride 25 mg - essential hypertension, alone or as an adjunct. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.
fintral
douglas pharmaceuticals limited - finasteride 5mg; - tablet - 5 mg - active: finasteride 5mg excipient: hypromellose macrogol 8 stearate type 1 sodium starch glycollate type a lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate starch - fintral is indicated for the treatment and control of benign prostatic hyperplasia (bph) and for the prevention of urologic events to; · reduce the risk of acute urinary retention · reduce the risk of surgery including transuretheral resection of the prostate (turp) and prostatectomy fintral causes regression of the enlarged prostate, improved urinary flow and improves the symptoms associated with bph. patients with enlarged prostate are the appropriate candidates for therapy with fintral.